Coverage with Evidence Development is a CMS policy that grants conditional Medicare coverage while requiring sponsors to collect prespecified outcomes data through a study or registry. CMS uses it when clinical evidence is promising but incomplete for the Medicare population, and the practical consequence for developers is immediate: coverage now depends on running a fit-for-purpose study, not just clearing a regulatory bar. Get the evidence plan wrong, and reimbursement stalls for years.
TL;DR:
- CMS relies heavily on stakeholder engagement and precise endpoint selection to ensure CED data effectively addresses Medicare-specific evidence gaps.
- Study designs must include validated data collection and expert oversight, with protocols pre-planned before enrollment to maintain credibility with CMS reviewers.
- CED status tends to persist indefinitely unless sponsors proactively publish interim results and incorporate predefined stopping rules into their studies.
- Practical focus on outcomes relevant to older, sicker populations, such as function and survival, accelerates the reconsideration process for coverage expansion.
- Early, strategic CMS engagement and physician involvement can significantly shorten the time and effort needed to move from initial coverage to full approval.
Table of Contents
- What Is Coverage With Evidence Development?
- What Legal Authority Lets CMS Require Evidence?
- When Does CMS Require CED?
- What Study and Registry Standards Does CMS Expect?
- How Should Sponsors Build a CED-Ready Evidence Plan?
- How Long Does CED Last, and How Does It End?
- What Can Past CED Cases Teach Developers Today?
- Why Evidence Strategy Deserves Board-Level Attention
- Where The StartupMD Fits Into Your Evidence Strategy
- Sources
- FAQ
What Is Coverage With Evidence Development?
CED lets CMS pay for an item or service under Medicare while requiring participants to enroll in an approved clinical study. The policy exists because a technology can be safe and plausible without yet having data specific enough to satisfy Medicare's evidentiary standards, particularly around older, sicker, or more comorbid patients than typical trial populations.
CMS has historically operated CED through two arms, spelled out in its guidance for the public, industry, and CMS staff:
- Coverage with Appropriateness Determination (CAD): Coverage tied to a registry that tracks appropriate patient selection and outcomes, without a formal research hypothesis.
- Coverage with Study Participation (CSP): Coverage tied to enrollment in a clinical trial or study designed to answer a specific research question.
Both arms attach to a National Coverage Determination, meaning CED is a condition written directly into the NCD itself, not a side agreement negotiated after the fact.
What Legal Authority Lets CMS Require Evidence?
CMS grounds CED in Section 1862 of the Social Security Act, which authorizes the agency to determine whether an item or service is "reasonable and necessary" for diagnosis or treatment. That standard gives CMS room to attach conditions, including data collection, when the reasonable-and-necessary determination hinges on unresolved evidence gaps.
The CMS guidance document also describes a supporting role for the Agency for Healthcare Research and Quality:
- AHRQ can conduct or fund technology assessments that inform CMS's coverage analysis.
- AHRQ's evidence synthesis work often precedes or runs parallel to an NCD process involving CED.
- CED complements, rather than duplicates, FDA's premarket safety and effectiveness review and NIH's basic and translational research funding.
FDA clearance answers whether a product works and is safe. CED answers a narrower, Medicare-specific question: does it work well enough, for this population, to justify ongoing taxpayer-funded coverage?
When Does CMS Require CED?
CMS reaches for CED when it identifies a real evidence gap that a standard NCD cannot resolve on the existing record. The agency's own evidence review framework leans on criteria aligned with GRADE, weighing risk of bias, precision, consistency, and directness of the available studies, with particular weight on applicability to the Medicare population rather than to a younger or healthier trial cohort.
Decision factors typically include:
- Promising but limited evidence, often from small trials or subgroups underrepresented in the Medicare beneficiary base.
- Uncertainty about whether benefits outweigh risks in patients with multiple comorbidities.
- Stakeholder input gathered through public comment periods and clinical community consultation.
The evidence questions CMS is usually trying to answer are concrete: does the intervention improve survival, function, or quality of life in beneficiaries age 65 and older, and does the benefit hold up outside the narrow inclusion criteria of a pivotal trial?
What Study and Registry Standards Does CMS Expect?
Acceptable evidence under CED generally takes one of two forms: a pragmatic clinical trial or a prospective observational registry, each built around a prespecified analysis plan rather than an after-the-fact data mining exercise.
Registries carry specific expectations, laid out consistently across CMS's guidance:
- Scientific oversight from a qualified steering committee or academic partner.
- Validated data collection methods and predefined outcome measures.
- Patient protections, including informed consent and de-identified reporting.
- Registration on ClinicalTrials.gov before enrollment begins, with interim analyses and eventual peer-reviewed publication expected as the study matures.
Pro Tip: Build your statistical analysis plan and interim-look schedule before submitting to CMS, not after enrollment starts. A protocol with pre-specified stopping rules and Medicare-relevant endpoints reads as far more credible to CMS reviewers than one retrofitted after data collection is already underway.
How Should Sponsors Build a CED-Ready Evidence Plan?
Startups and device developers who treat CED as an afterthought tend to spend years longer under the requirement than necessary. A tighter sequence looks like this:
- Map the evidence gap. Identify precisely which CMS uncertainty (population, endpoint, comparator) your data needs to resolve, and design nothing that doesn't address it.
- Map stakeholders early. Loop in clinical champions, patient advocacy groups, and AHRQ where relevant, before the NCD comment period closes.
- Engage CMS pre-submission. Informal dialogue before a formal proposal reduces the odds of a study design CMS later flags as insufficient.
- Design for Medicare relevance. Choose endpoints tied to function, mortality, or quality of life in an age and comorbidity mix that matches actual beneficiaries, not a younger trial population.
- Build the data pipeline before enrollment. Registry governance, data protection, and budget for long-term data management need to exist on day one.
For healthcare SaaS companies building the software layer beneath a registry or trial, the operational discipline mirrors go-to-market planning. Both require getting the product-market fit and reimbursement strategy aligned before scaling.
Pro Tip: If your registry needs external data-reporting infrastructure, review standards like the ones outlined in this EMS data reporting compliance guide before building custom pipelines. Reporting and governance patterns from other regulated data environments translate more directly than most teams expect.
How Long Does CED Last, and How Does It End?
CED ends when CMS reconsiders the original NCD based on completed or sufficiently mature study data, either lifting the requirement, expanding coverage, or in rarer cases narrowing it. A 2005 to 2024 analysis found that of 26 items and services placed into the CED program, only 10, or 38%, underwent formal reconsideration. That leaves a majority sitting in CED status indefinitely, often longer than sponsors anticipated at the outset.
Two practices consistently shorten that timeline:
- Embedding interim analyses with predefined stopping rules tied directly to coverage-relevant endpoints, rather than waiting for full enrollment before looking at results.
- Publishing results transparently in peer-reviewed venues as they mature, rather than holding data until a single comprehensive submission.
Sponsors who treat the reconsideration request as a one-time event, instead of a milestone built into the protocol from day one, tend to be the ones stuck the longest.
What Can Past CED Cases Teach Developers Today?
Implantable cardioverter defibrillators and FDG PET imaging remain two of the most cited CED examples, and both illustrate the same lesson from different angles.
- ICD coverage expanded incrementally as registry data clarified which patient subgroups actually benefited, showing that CED can widen access when the evidence supports it.
- FDG PET's CED history showed how unclear endpoint selection early on can prolong the evidence-gathering phase well beyond initial sponsor expectations.
- In both cases, sponsors who aligned endpoints tightly to Medicare-relevant outcomes moved through reconsideration faster than those who leaned on broader, less targeted metrics.
The throughline: coverage decisions move fastest when the data answers the exact question CMS asked, not a related but different one.
Why Evidence Strategy Deserves Board-Level Attention
Too many healthcare SaaS and device teams treat CED as a compliance checkbox handed to a regulatory affairs contractor after the fact. It is strategic evidence work that belongs in the same conversation as fundraising, clinical strategy, and go-to-market timing. Founders who bring physician-level clinical judgment into the evidence plan early tend to design studies CMS trusts on the first pass, which is the single biggest lever for shortening time-in-CED.
— Paul Bergeron MD, MBA
Where The StartupMD Fits Into Your Evidence Strategy
Building a CED-ready study is not something most healthcare SaaS teams have done before. It usually takes a physician-level understanding of what CMS actually wants to see, paired with startup-speed execution. That combination is what a Fractional Chief Medical Officer engagement is built for. The StartupMD helps founders map evidence gaps, structure registry governance, and prepare for CMS and AHRQ engagement without hiring a full-time clinical executive before you need one.
Clinical strategy and product evaluation work go hand in hand with the commercial side of the business. Before finalizing your evidence plan, review how it fits into your broader revenue model and investor narrative, since CMS reconsideration timing directly shapes fundraising milestones and revenue projections. If your team is scoping a fractional CMO engagement to lead evidence strategy and CMS engagement, the services overview outlines how that engagement typically starts, with a scoping conversation to map your specific evidence gaps before drafting a formal plan.
Sources
This article is general information, not a substitute for advice from a qualified lawyer. Consult a qualified legal professional about your own circumstances before acting on anything here.
FAQ
What Are the Four Main Types of Medicare Coverage?
Medicare's four parts are Part A (hospital insurance), Part B (medical insurance), Part C (Medicare Advantage), and Part D (prescription drug coverage). CED requirements typically attach to items and services covered under Part A or Part B through a National Coverage Determination.
What Qualifies as Creditable Coverage?
Creditable coverage is health coverage, such as an employer plan, that is at least as good as Medicare's standard prescription drug benefit, so beneficiaries who delay enrolling in Part D avoid a late penalty. It is a distinct concept from CED, which governs conditional coverage of specific items and services rather than enrollment timing.
What Are Examples of Services Medicare Typically Won't Cover?
Original Medicare generally excludes routine dental care, most vision and hearing services, long-term custodial care, and cosmetic procedures. Items placed under CED sit in a different category entirely: they are covered, but only within the terms of an approved study or registry.
What Is the Difference Between an NCD and an LCD?
A National Coverage Determination is issued by CMS and applies nationwide, while a Local Coverage Determination is issued by a Medicare Administrative Contractor and applies only within that contractor's jurisdiction. CED requirements are written into NCDs, not LCDs, since they represent a national coverage policy rather than a regional one.
How Does CED Differ From Coverage Under Expanded Conditions?
Coverage with Evidence Development requires ongoing data collection as a condition of payment, while coverage under expanded conditions generally refers to broader eligibility criteria within an existing NCD without a mandatory research or registry component. The two are sometimes confused because both expand access beyond a narrow initial indication, but only CED ties that access to prespecified evidence generation.